SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that an article describing the potential benefits of its product candidate for hyperlipidemia, MB07811, was published in the Proceedings of the National Academy of Sciences (PNAS), Vol. 104, Issue No. 39, pp. 15490 - 15495. The article, by Dr. Mark Erion et al., is entitled “Targeting Thyroid Hormone Receptor-ß Agonists to the Liver Reduces Cholesterol and Triglycerides and Improves the Therapeutic Index”.
